TRANSGENE S.A. company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance. Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla.

Novartis Corporation has what the doctor ordered. As the North American headquarters of Switzerland-based Novartis AG, the unit handles administration, sales, and marketing for a vast product line of prescription drugs, consumer health products, vaccines, and veterinary products. But wait, there is more! Novartis Corporation also oversees the Novartis Institutes for Biomedical Research, which is headquartered in the US. Novartis Corporation headlines dozens of US business units including CIBA Vision, Novartis Pharmaceuticals, and the US operations of its Sandoz generics business.

Garden of Life, Inc. Company manufactures and supplies nutritional supplements, specialty food items, and personal care products. Its supplements include weight management, digestive health, and immune-system support products. The company's Original Medicine division produces nutritional products for distribution by health practitioners; its other lines are sold through natural foods retailers. Many of Garden of Life's products are based on a program called The Maker's Diet which was created by company founder and chairman Jordan Rubin in 2000 after overcoming Crohn's disease. Garden of Life has agreed to be acquired by Atrium Innovations.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

YM BioSciences USA Inc. company develops products for treating cancer and other related conditions. Its product candidates come out of Canadian parent company YM BioSciences Inc.' biotechnology portfolio. It is conducting clinical trials on nimotuzumab, a monoclonal antibody treatment targeting brain-cancer, for use in pediatric patients and for use in treating other solid tumor cancers in all patients. YM BioSciences also targets cancer-related pain. YM BioSciences USA changed its name from EXIMIAS Pharmaceutical a number of years ago when it was acquired by, and became a wholly owned subsidiary of, YM Biosciences Inc.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

Medpace is on pace to bring new drugs to market. The contract research organization (CRO) offers clinical trial management and regulatory consulting to pharmaceutical and biotech companies that are developing new drug candidates in the areas of cardiology, metabolism, and oncology. Its services include clinical development planning, data management, laboratory services, quality assurance auditing, regulatory document preparation, safety surveillance, and statistical analysis. Its Web-based ClinTrak tool allows users to access and track real-time clinical study data and metrics. Medpace serves customers worldwide through offices in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.